Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$25.92 USD
-0.76 (-2.85%)
Updated Jun 14, 2024 03:59 PM ET
After-Market: $25.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MIRM 25.92 -0.76(-2.85%)
Will MIRM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Are Bullish on Top Healthcare Picks
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
Mirum Pharmaceuticals presents long-term data from LIVMARLI studies
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference